BTF granted US patent for 'Bioballs'

By Renate Krelle
Thursday, 23 September, 2004

Private Sydney-based biotech BTF has been granted a US patent for its BioBall quality-control product.

The patent protects its BioBall technology, which uses a flow cytometer to count out precisely 30 viable bacteria. The bacteria are freeze dried in a drop of nutrient fluid as a 'Bioball' pellet.

The pellets can be reconstituted and used as a control, eliminating the need for labs to perform routine serial dilutions.

Related News

Link between oestrogen and heart health found in women

Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...

Frequent nightmares accelerate aging, increase risk of death

Nghtmares independently predict faster biological aging and earlier mortality — even after...

Cardiac organoids bring hope for treating heart disease

Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd